News & Analysis on Clinical Trial Services & Contract Research And Development
A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in the US and the IMP approved in the EU, the sponsor incorrectly assumed and, without checking further requirements, that Israel had the same QP (qualified person) approval process as the EU.
Learn how Catalent was able to help the sponsor meet the QP requirements and start their study on time.
Paid for and content provided by Catalent
The nature and scope of clinical research has changed significantly over the past decade. Studies are more complex, globalized and patient-centric than ever. Yet, the processes used to package and ship study drugs to trial sites are stuck in an earlier...
With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader area landscape in order to develop a distribution strategy that avoids delays and minimizes cost and...
The pharmaceutical industry had to adapt quickly to the pandemic if it was to continue to supply important medicines, while also racing to develop vaccines and treatments.
For more product information visit Catalent.